learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
1 / 1 resultsResearch
5 / 702 results
research Ficoll Density Gradient Sedimentation Isolation of Pelage Hair Follicle Mesenchymal Stem Cells from Adult Mouse Back Skin: A Novel Method for Hair Follicle Mesenchymal Stem Cells Isolation
The new method isolates more hair follicle stem cells from mice quickly and these cells help promote hair growth.
research Ficoll Density Gradient Sedimentation Isolation of Pelage Hair Follicle Mesenchymal Stem Cells From Adult Mouse Back Skin: A Novel Method for Hair Follicle Mesenchymal Stem Cells Isolation
A new method quickly and efficiently isolates hair follicle stem cells from adult mice, promoting hair growth.
research Hair Follicle: A Novel Source of Multipotent Stem Cells for Tissue Engineering and Regenerative Medicine
Hair follicle stem cells are a promising source for tissue repair and treating skin or hair diseases.
research Advanced Medical Therapies in the Management of Non-Scarring Alopecia: Areata and Androgenic Alopecia
Advanced therapies like gene, cell, and tissue engineering show promise for hair regrowth in alopecia, but their safety and effectiveness need more verification.
research Dermal Papilla Regulation of Hair Growth and Pigmentation
Dermal papilla cells are key for hair growth and color, influencing hair type and size, and their interaction with stem cells could help treat hair loss and color disorders.
Community Join
5 / 107 resultscommunity PP405 Won't Work Long Term: Hair Follicle Damage Due to Abuse of the ISR System
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
community PP405 Update and My Take on Pelage
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
community Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
community Track hairline of Pelage executives
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.